Differential adoption of castration‐resistant prostate cancer treatment across facilities in a national healthcare system
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5490
Abstract: Over the past decade, abiraterone and enzalutamide have largely replaced ketoconazole as oral treatments for castration‐resistant prostate cancer (CRPC). We investigated the differential adoption of abiraterone and enzalutamide across facilities in a national healthcare system… read more here.
Keywords: prostate cancer; differential adoption; across facilities; resistant prostate ... See more keywords